A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
A phase 1/2 trial of 23ME-00610 in renal cell carcinoma, ovarian cancer, neuroendocrine tumours and small-cell lung cancer, run by 23andMe, Inc., active and no longer recruiting.
Overview
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT05199272 by 23andMe, Inc., with 141 participants enrolled, started 2021-12-29 and due to reach its primary completion in 2025-03. Interventions recorded: 23ME-00610.
Similar pages
not linked directly; found by shared links- TrialA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
- TrialDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
- TrialPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Shares Renal cell carcinoma, Small-cell lung cancer and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- TrialA First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
- TrialStudy of Oral MRT-2359 in Selected Cancer Patients
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.